Pharmacotherapy for inherited colorectal cancer

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 7, 2010, Pages 1101-1108

  Lynch, Patrick M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Celecoxib; Chemoprevention; Colorectal adenomas; Colorectal cancer; COX 2 inhibition; Familial adenomatous polyposis; Rofecoxib; Sulindac

Indexed keywords

ACETYLSALICYLIC ACID; ASCORBIC ACID; CELECOXIB; EFLORNITHINE; INDOMETACIN; PLACEBO; ROFECOXIB; STARCH; SULINDAC; SULINDAC SULFONE;

ABDOMINAL PAIN; ADENOMATOUS POLYP; ARTHRITIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOSCOPY; FAMILIAL ADENOMATOUS POLYPOSIS; FAMILIAL CANCER; FAMILIAL DISEASE; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; LIVER FUNCTION TEST; LOW DRUG DOSE; POLYPECTOMY; REVIEW; SIDE EFFECT; STROKE; TABLET; TREATMENT FAILURE;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMBINED MODALITY THERAPY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 77951264770     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003698123     Document Type: Review

References (42)

1. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35(6):1332-1338
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94(2):153-156 (Pubitemid 32911406)
3. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329(27):1977-1981 (Pubitemid 24015040)
4. Church J, Simmang C. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 2003;46(8):1001-1012 (Pubitemid 36992980)
5. Desch CE, Benson AB III, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23(33):8512-8519 (Pubitemid 46260248)
6. Levin B, Barthel JS, Burt RW, et al. Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw 2006;4(4):384-420 (Pubitemid 44453325)
7. Lynch PM. New issues in genetic counseling of hereditary colon cancer. Clin Cancer Res 2007;13(22 Pt 2):6857s-61s
8. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53(1):27-43 (Pubitemid 36163620)
9. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003;124(2):544-560 (Pubitemid 36169269)
10. Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007;25(13):1785-1791 (Pubitemid 46797962)
11. Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol 2006;24(1):11-12
12. Bussey HJ, DeCosse JJ, Deschner EE, et al. A randomized trial of ascorbic acid in polyposis coli. Cancer 1982;50(7):1434-1439
13. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24(1):83-87
14. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101(3):635-639
15. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328(18):1313-1316 (Pubitemid 23131373)
16. Cruz-Correa M, Hylind LM, Romans KE, et al. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002;122(3):641-645 (Pubitemid 34173815)
17. Winde G, Schmid KW, Schlegel W, et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995;38(8):813-830
18. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87(5):803-809 (Pubitemid 26404280)
19. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58(3):409-412 (Pubitemid 28087398)
20. Chalada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Research 2000;60:4705-4708
21. Kashfi K, Rigas B. Expanding the molecular target repertoire of chemoprevention. Biochemical Pharmacology 2005;70:969-986
22. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342(26):1946-1952 (Pubitemid 30419089)
23. Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50(6):857-860
24. Hallak A, Alon-Baron L, Shamir R, et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003;48(10):1998-2002 (Pubitemid 37410090)
25. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352(11):1092-1102 (Pubitemid 40365350)
26. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352(11):1071-1080 (Pubitemid 40365348)
27. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Research 1997;57:2909-2915
28. Thomson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3¢,5¢, -cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attentuated B-catenin. Cancer Research 2000; 60:3338-3342 (Pubitemid 30482142)
29. van Stolk R, Stoner G, Hayton WL, et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 2000;6(1):78-89 (Pubitemid 30064979)
30. Di Sario JA OM, Szabo A, et al. Exisilind for duodenal adenoma in persons with familial adenomatous polyposis. Gastroenterology 2005;W970(P):A-567
31. Arber N, Kuwada S, Leshno M, et al. Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study. Gut 2006;55:367-373 (Pubitemid 43268275)
32. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346(14):1054- 1059 (Pubitemid 34984619)
33. Burn J, Chapman PD, Mathers J, et al. The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Concerted Action Polyposis Prevention. Eur J Cancer 1995;31A(7-8):1385-1386
34. Meyskens FL Jr, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 2008;1(1):32-38
35. Perkins S, Verschoyle RD, Hill K, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002;11(6):535-540 (Pubitemid 34615160)
36. Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006;4(8):1035-1038 (Pubitemid 44118839)
37. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349(3):247-257
38. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108(5):1405-1411
39. Mecklin JP, Aarnio M, Laara E, et al. Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. Gastroenterology 2007;133(4):1093-1098 (Pubitemid 47494464)
40. Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 2000;24(2):137-142 (Pubitemid 30427699)
41. Glebov OK, Rodriguez LM, Lynch P, et al. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 2006;15(7):1382-1391 (Pubitemid 44125297)
42. Burn J, Bishop T, Jukka-Pekka M, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the lynch syndrome. N Engl J Med 2008;359:2567-2578